Johnson & Johnson logo
Johnson & Johnson (JNJ)
Compare

Johnson & Johnson (JNJ) EV/EBITDA Ratio: 18.67x

popular:market cap|pe ratio|revenue|price history|total return

Is Johnson & Johnson’s EV/EBITDA ratio high or low?

Johnson & Johnson's EV/EBITDA ratio of 18.67x is 16% above its 5-year average of 16.13x, around the middle of its 5-year range (10.62x–22.73x).

As of Thursday, June 11, 2026. 33.12% above its 12-month average of 14.03x.

EV/Sales|P/E Ratio|EBITDA|All Metrics

JNJ EV/EBITDA Ratio Chart

JNJ EV/EBITDA Ratio
18.67x+66.10% 1Y
Zoom

JNJ Average EV/EBITDA Ratio Chart

JNJ Current vs Average EV/EBITDA Ratio Chart

JNJ EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

18.67x

EV/EBITDA RATIO AVG TTM

14.03x

EV/EBITDA RATIO AVG 3Y

15.52x

EV/EBITDA RATIO AVG 5Y

16.13x

EV/EBITDA RATIO AVG 10Y

15.83x

EV/EBITDA RATIO AVG 15Y

14.65x

EV/EBITDA RATIO AVG 20Y

13.39x

CURRENT VS TTM AVG

+33.12%

CURRENT VS 3Y AVG

+20.27%

CURRENT VS 5Y AVG

+15.74%

CURRENT VS 10Y AVG

+17.95%

CURRENT VS 15Y AVG

+27.48%

CURRENT VS 20Y AVG

+39.41%

JNJ Competitors' EV/EBITDA Ratio

NAMEMARKET CAPEV/EBITDA RATIOTTM3Y5Y
Johnson & Johnson (JNJ)$577.73B18.67x14.03x15.52x16.13x
Pfizer Inc. (PFE)$149.61B12.74x10.53x15.94x13.74x
Merck & Co., Inc. (MRK)$298.23B19.83x11.18x19.68x18.02x
AbbVie Inc. (ABBV)$399.86B27.47x30.40x23.53x19.98x
Eli Lilly and Company (LLY)$1.10T32.27x36.50x56.87x48.16x
Bristol-Myers Squibb Company (BMY)$116.13B10.99x9.65x16.59x15.47x

EV/EBITDA vs. its own history

At 18.7, EV/EBITDA is richer than usual, sitting higher than 96% of its 20-year history.

20-year low

6.3

median

13.6

20-year high

22.7

cheaperricher

Johnson & Johnson EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Johnson & Johnson EV/EBITDA Ratio FAQ

What is the EV/EBITDA ratio for Johnson & Johnson (JNJ)?
The EV/EBITDA ratio for JNJ stock is 18.67x.
Is Johnson & Johnson's EV/EBITDA ratio high or low?
Johnson & Johnson's EV/EBITDA ratio of 18.67x is 16% above its 5-year average of 16.13x, around the middle of its 5-year range (10.62x–22.73x).
What is the TTM average EV/EBITDA ratio for Johnson & Johnson (JNJ)?
The TTM average EV/EBITDA ratio for JNJ stock is 14.03x.
What is the 3Y average EV/EBITDA ratio for Johnson & Johnson (JNJ)?
The 3Y average EV/EBITDA ratio for JNJ stock is 15.52x.
What is the 5Y average EV/EBITDA ratio for Johnson & Johnson (JNJ)?
The 5Y average EV/EBITDA ratio for JNJ stock is 16.13x.
What is the 10Y average EV/EBITDA ratio for Johnson & Johnson (JNJ)?
The 10Y average EV/EBITDA ratio for JNJ stock is 15.83x.
What is the 15Y average EV/EBITDA ratio for Johnson & Johnson (JNJ)?
The 15Y average EV/EBITDA ratio for JNJ stock is 14.65x.
What is the 20Y average EV/EBITDA ratio for Johnson & Johnson (JNJ)?
The 20Y average EV/EBITDA ratio for JNJ stock is 13.39x.

Johnson & Johnson EV/EBITDA Ratio History

DATEEV/EBITDA RATIO
2026-06-1118.67x
2026-06-1018.52x
2026-06-0918.41x
2026-06-0818.03x
2026-06-0518.08x
2026-06-0417.72x
2026-06-0317.33x
2026-06-0217.30x
2026-06-0117.35x
2026-05-2917.49x
2026-05-2817.92x
2026-05-2717.96x
2026-05-2617.87x
2026-05-2218.20x
2026-05-2117.99x
2026-05-2017.81x
2026-05-1917.86x
2026-05-1817.77x
2026-05-1517.60x
2026-05-1417.92x
2026-05-1317.89x
2026-05-1217.41x
2026-05-1117.19x
2026-05-0817.18x
2026-05-0717.27x
2026-05-0617.44x
2026-05-0517.51x
2026-05-0417.41x
2026-05-0117.64x
2026-04-3017.85x
2026-04-2917.65x
2026-04-2817.69x
2026-04-2717.49x
2026-04-2417.66x
2026-04-2317.91x
2026-04-2217.55x
2026-04-2114.20x
2026-04-2014.47x
2026-04-1714.68x
2026-04-1614.70x
2026-04-1514.95x
2026-04-1415.03x
2026-04-1314.91x
2026-04-1014.94x
2026-04-0915.11x
2026-04-0815.11x
2026-04-0714.93x
2026-04-0615.09x
2026-04-0215.21x
2026-04-0115.27x
2026-03-3115.29x
2026-03-3015.18x
2026-03-2715.06x
2026-03-2614.98x
2026-03-2515.02x
2026-03-2414.75x
2026-03-2314.75x
2026-03-2014.75x
2026-03-1914.89x
2026-03-1814.87x
2026-03-1714.92x
2026-03-1615.22x
2026-03-1315.12x
2026-03-1215.15x
2026-03-1115.21x
2026-03-1015.25x
2026-03-0915.18x
2026-03-0615.05x
2026-03-0515.01x
2026-03-0415.35x
2026-03-0315.43x
2026-03-0215.54x
2026-02-2715.53x
2026-02-2615.24x
2026-02-2515.34x
2026-02-2415.40x
2026-02-2315.38x
2026-02-2015.18x
2026-02-1915.44x
2026-02-1815.33x
2026-02-1715.23x
2026-02-1315.23x
2026-02-1215.30x
2026-02-1115.08x
2026-02-1015.33x
2026-02-0915.35x
2026-02-0615.43x
2026-02-0515.30x
2026-02-0415.09x
2026-02-0315.01x
2026-02-0214.86x
2026-01-3014.65x
2026-01-2914.65x
2026-01-2814.68x
2026-01-2714.48x
2026-01-2614.30x
2026-01-2314.21x
2026-01-2214.11x
2026-01-2114.08x
2026-01-2014.09x
2026-01-1614.12x
2026-01-1514.18x
2026-01-1414.11x
2026-01-1313.81x
2026-01-1213.57x
2026-01-0913.25x
2026-01-0813.33x
2026-01-0713.44x
2026-01-0613.27x
2026-01-0513.24x
2026-01-0213.43x
2025-12-3113.40x
2025-12-3013.40x
2025-12-2913.44x
2025-12-2613.44x
2025-12-2413.45x
2025-12-2313.33x
2025-12-2213.43x
2025-12-1913.37x
2025-12-1813.49x
2025-12-1713.61x
2025-12-1613.55x
2025-12-1513.85x
2025-12-1213.69x
2025-12-1113.59x
2025-12-1013.38x
2025-12-0912.97x
2025-12-0813.08x
2025-12-0513.09x
2025-12-0413.13x
2025-12-0313.30x
2025-12-0213.31x
2025-12-0113.30x
2025-11-2813.40x
2025-11-2613.44x
2025-11-2513.39x
2025-11-2413.35x
2025-11-2113.22x
2025-11-2013.16x
2025-11-1913.13x
2025-11-1812.98x
2025-11-1712.95x
2025-11-1412.73x
2025-11-1312.68x
2025-11-1212.63x
2025-11-1112.60x
2025-11-1012.26x
2025-11-0712.15x
2025-11-0612.18x
2025-11-0512.12x
2025-11-0412.17x
2025-11-0312.13x
2025-10-3112.29x
2025-10-3012.30x
2025-10-2912.15x
2025-10-2812.17x
2025-10-2712.38x
2025-10-2412.39x
2025-10-2312.51x
2025-10-2212.54x
2025-10-2113.92x
2025-10-2014.05x
2025-10-1714.02x
2025-10-1613.94x
2025-10-1513.88x
2025-10-1413.85x
2025-10-1313.86x
2025-10-1013.85x
2025-10-0913.87x
2025-10-0813.78x
2025-10-0713.72x
2025-10-0613.67x
2025-10-0313.70x
2025-10-0213.52x
2025-10-0113.53x
2025-09-3013.49x
2025-09-2913.23x
2025-09-2613.10x
2025-09-2512.96x
2025-09-2412.89x
2025-09-2312.89x
2025-09-2212.73x
2025-09-1912.86x
2025-09-1812.72x
2025-09-1712.93x
2025-09-1612.88x
2025-09-1512.94x
2025-09-1212.99x
2025-09-1113.02x
2025-09-1012.83x
2025-09-0912.91x
2025-09-0812.99x
2025-09-0513.01x
2025-09-0413.03x
2025-09-0312.98x
2025-09-0212.99x
2025-08-2912.93x
2025-08-2812.81x
2025-08-2712.90x
2025-08-2612.88x
2025-08-2513.01x
2025-08-2213.07x
2025-08-2113.05x
2025-08-2013.04x
2025-08-1912.97x
2025-08-1812.86x
2025-08-1512.89x
2025-08-1412.76x
2025-08-1312.74x
2025-08-1212.63x
2025-08-1112.70x
2025-08-0812.67x
2025-08-0712.54x
2025-08-0612.48x
2025-08-0512.49x
2025-08-0412.51x
2025-08-0112.26x
2025-07-3112.08x
2025-07-3012.25x
2025-07-2912.31x
2025-07-2812.18x
2025-07-2512.32x
2025-07-2412.41x
2025-07-2312.21x
2025-07-2212.13x
2025-07-2111.88x
2025-07-1811.83x
2025-07-1711.78x
2025-07-1611.91x
2025-07-1511.23x
2025-07-1411.35x
2025-07-1111.36x
2025-07-1011.41x
2025-07-0911.31x
2025-07-0811.28x
2025-07-0711.24x
2025-07-0311.29x
2025-07-0211.26x
2025-07-0111.29x
2025-06-3011.07x
2025-06-2711.04x
2025-06-2611.01x
2025-06-2511.03x
2025-06-2411.03x
2025-06-2310.97x
2025-06-2010.86x
2025-06-1810.92x
2025-06-1711.04x
2025-06-1611.24x
2025-06-1311.37x
2025-06-1211.34x
2025-06-1111.24x
2025-06-1011.32x
2025-06-0911.24x
2025-06-0611.22x
2025-06-0511.13x
2025-06-0411.10x
2025-06-0311.18x
2025-06-0211.25x
2025-05-3011.24x

Showing the most recent 260 of 5,032 data points. The chart above shows the full history.

Related Metrics

EV/SalesP/E RatioEBITDAAll Metrics

About Johnson & Johnson

Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.

New Brunswick, NJ
138,100 employees
www.jnj.com
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Joaquin Duato
View full financials